Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a Florida-based biopharmaceutical company, announced on Thursday that it has named Jeff Cole as its new chief operating officer.

In the new role, Cole will be responsible for the firm's manufacturing and supply chain operations, intellectual property, commercialisation strategies and support collaboration activities for tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with certain medical conditions.

Cole brings more than 25 years of experience in global pharmaceutical manufacturing and commercial operations, finance, and corporate development to the firm. He has served in senior executive roles at both private and publicly-traded companies such as Espero BioPharma, Valeant Pharmaceuticals International (now Bausch Health Companies), and Legacy Pharmaceuticals. He co-founded Espero and served as board director, president, and chief financial officer. He has served as principal in the Financial Management Consulting practice at PricewaterhouseCoopers.

Quang Pham, Cadrenal Therapeutics founder, chairman and chief executive officer, said, 'Jeff is an extremely accomplished pharmaceutical operations executive with a deep understanding of product development, manufacturing, and commercialisation. His experience will serve Cadrenal well as we advance our tecarfarin clinical program and evaluate partnering opportunities.'